"I thought that it was a usual practice by all pharma is it not?."
yeah Slogger - i was under the impression this sort of approach was/is normal in the industry. Although clearly Lilly has pushed it a little too far (and got caught) in this instance.
Was thinking about this - for me this is a positive indicator for Axiron / ACR. yeah sure the fine is bad for Lilly - but it does show that Lilly is pushing Axiron marketing / sales wise very hard here. A good sign of support in my opinion!
Regards,
mita
Add to My Watchlist
What is My Watchlist?
